The next generation of drug-eluting stents: What's on the horizon?

American Journal of Cardiovascular Drugs

Volumn 7, Issue 2, 2007, Pages 81-93

  Ramcharitar, Steve ^a   Vaina, Sophia ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLIMUS A9; CLOPIDOGREL; DEXAMETHASONE; EVEROLIMUS; HEPARIN; HYDROXYAPATITE; IMMUNOSUPPRESSIVE AGENT; OMEGA 3 FATTY ACID; PACLITAXEL; PIMECROLIMUS; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS;

BIODEGRADABILITY; BIOENGINEERING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; DRUG MECHANISM; FOLLOW UP; HUMAN; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVIEW;

BIOCOMPATIBLE MATERIALS; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; POLYMERS; PROSTHESIS DESIGN; SIROLIMUS; STENTS;

EID: 34249004599     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707020-00001     Document Type: Review

References (65)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80
2. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109: 1942-7
3. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-21
4. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45: 947-53
5. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088-92
6. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-30
7. Hoye A, Iakovou I, Ge L, et al. Long-term outcomes after stenting of bifurcation lesions with the 'crush' technique: predictors of an adverse outcome. J Am Coll Cardiol 2006; 47: 1949-58
8. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006; 113: 1108-13
9. Smith Jr SC, Feldman TE, Hirshfeld Jr JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-286
10. Kim YH, Park SW, Hong MK, et al. Comparison of simple and complex stenting techniques in the treatment of unprotected left main coronary artery bifurcation stenosis. Am J Cardiol 2006; 97: 1597-601
11. Mehilli J, Dibra A, Kastrati A, et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006; 27: 260-6
12. Hoye A, Tanabe K, Lemos PA, et al. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol 2004; 43: 1954-8
13. Ge L, Iakovou I, Cosgrave J, et al. Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur Heart J 2005; 26: 1056-62
14. Burke SE, Kuntz RE, Schwartz LB. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev 2006; 58 (3): 437-46
15. Meredith IT, Ormiston J, Whitbourn R, et al. Endeavor I, 'first in man', safety and efficacy study, 12 months clinical, angiographin and intravescular ultrasound results [abstract no. 2623]. Circulation 2004; 110: III-563-4
16. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798-806
17. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006; 48: 2440-7
18. Agostoni P, Valgimigli M, Abbate A, et al. Is late luminal loss an accurate predictor of the clinical effectiveness of drug-eluting stents in the coronary arteries? Am J Cardiol 2006; 97: 603-5
19. Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol 2006; 19: 405-13
20. Chevalier B. The ZoMaxx clinical trial programme. Paris: EuroPCR, 2006
21. Abizaid A, Lansky A, Fitzgerald P, et al. Percutaneous coronary revascularization using a trilayer phosphorylcholine-coated zotarolimus-eluting stent: the ZoMaxx IVUS trial [lecture]. 55th Annual Scientific Session of the American College of the Cardiology; 2006 Mar 11-14; Atlanta (GA): American College of Cardiology, 2006
22. TCT daily: ZOMAXX I: mixed results with zotarolimus-eluting stent. J Interv Cardiol 2007; 20: 35
23. Tsuchida K, Pick JJ, Neumann FJ, et al. One-year results of a durable polymereverolimus-eluting stent in de novo coronary narrowings (the SPIRIT FIRST trial). EuroIntervention 2005; 1: 266-72
24. Serruys PW, Wiemer M, Carrie D, et al. The SPIRIT II trial. EuroIntervention 2006; 2: 286-94
25. Stone G. SPIRIT III nine-month pivotal clinical data results i2 [lecture]. Summit American College of Cardiology's 56th Annual Scientific Session; 2007 Mar 24-27; New Orleans (LA): American College of Cardiology, 2007
26. Grube E, Hauptmann K, Buellesfeld L, et al. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9™ eluting stent with a biodegradablepolymer coating. EuroIntervention 2005; 1: 53-7
27. Chevalier B, Serruys PW, Siber S, et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus, paclitaxel-eluting coronary stent inpatients with stenosis in native arteries: the Nobori 1 trial. EuroIntervention 2007; 2: 426-34
28. Costa RA, Lansky AJ, Mintz GS, et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005; 95: 113-6
29. Tsuchiya Y, Lansky AJ, Costa RA, et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 2006; 98: 464-9
30. Morice MC, Bestehorn HP, Carrie D, et al. Direct stenting of the de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents: the randomized JUPITER II trial. EuroIntervention 2006; 2: 45-52
31. FDA happenings/around the industry. J Interven Cardiol 2006; 19: 472-4
32. Dawkins K. The Eurostar trial [lecture]. Paris Course on Revascularization; 2005 May 24-27; Paris: EuroPCR, 2005
33. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-7
34. Di Mario C, Griffiths H, Goktekin O, et al. Drug-eluting bioabsorbable magnesium stent. J Interv Cardiol 2004; 17: 391-5
35. Erbel R. Coronary results of the first absorable metal stent: the PROGRESS-I trial [abstract 2405-9]. 55th Annual Scientific Session of the American College of Cardiology; 2006 Mar 11-14; Atlanta (GA): American College of Cardiology, 2006
36. Vogt F, Stein A, Rettemeier G, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 2004; 25: 1330-40
37. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000; 102: 399-404
38. Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 2007; 69: 128-31
39. Grube E, Sonoda S, Ikeno F, et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004; 109: 2168-71
40. Serruys P. Emerging technology 1: stents. New drugs [lecture]. 55th Annual Scientific Session of the American College of Cardiology; 2006 Mar 11-14; Atlanta (GA): American College of Cardiology, 2006
41. Gambhir DS. The infinnium polymere-based paclitaxel drug-eluting stent: results from real world clinical trials SIMPLE 1 and SIMPLE 2 [lecture]. 16th Transcatheter Cardiovascular Therapeutics (TCT 2004) Annual Scientific Symposium; 2004 Sep 27-Oct 1; Washington, DC: Cardiovascular Research Foundation, 2004
42. Vranckx P, Serruys PW, Gambhir S, et al Biodegradable-polymer-based, paclitaxel-eluting Infinnium™ stent: 9-month clinical and angiographic follow-up results from the SIMPLE II prospectivemulti-centre registry study. EuroIntervention 2006; 2: 310-7
43. Dani SI. A biodegradable polymer-based sirolimus-eluting stent for treatment of secondary complication in patients with coronary artery disease [abstract no. AS-64]. Angioplasty Summit 2006-TCT Asia; 2006 Apr 26-28; Seoul, Korea: Cardiovascular Research Foundation, 2006
44. Lele S. Heparin sirolimus stent [lecture]. Paris: EuroPCR, 2006
45. Virmani R. Atrium medical bioabsorbable oil based delivery of a sirolimus analogue from a stent and balloon [lecture]. 17th Transcatheter Cardiovascular Therapeutics (TCT 2005) Scientific Sessions; 2005 Oct 16-21; Washington, DC: Cardiovascular Research Foundation, 2005
46. Wieneke H, Dirsch O, Sawitowski T, et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc Interv 2003; 60: 399-407
47. Kollum M, Farb A, Schreiber R, et al. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter Cardiovasc Interv 2005; 64: 85-90
48. Gerckens U, Buellesfeld L, Horskotte D, et al. Evaluation of a tacrolimus-eluting coronary stent with nanoporous ceramic coating in treatment of native coronary artery lesions: phase I and II of the PRESENT study [abstract]. J Am Coll Cardiol 2003; 41 (Suppl. A): 7A
49. Wessely R, Hausleiter J, Michaelis C, et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 2005; 25: 748-53
50. Hausleiter J, Kastrati A, Wessely R, et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 2005; 26: 1475-81
51. Conor Medsystems. Clinical, clinical trials [online]. Available from URL: http://www.conormed.com/clin/ [Accessed 2007 Apr 26]
52. Serruys PW, Sianos G, Abizaid A, et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 2005; 46: 253-60
53. Aoki J, Ong AT, Abizaid A, et al. One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer: insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES). EuroIntervention 2005; 2: 165-72
54. Kaul U. Erodablepolymer-reservoir paclitaxel drug eluting stents: II. Cobalt chromium platforms in complex lesions [lecture]. 16th Transcatheter Cardiovascular Therapeutics (TCT 2004) Annual Scientific Symposium; 2004 Sep 27-Oct 1; Washington, DC: Cardiovascular Research Foundation, 2004
55. Serruys PW. The new CoStar™ stent: 12 month results with the new DES technology [lecture]. Paris Course on Revascularisation; 2005 May 24-27; Paris: EuroPCR, 2005
56. Wijns W. CoStar™ Paclitaxel-eluting stent: relevance in drug-eluting stent clinical data landscape [lecture]. Paris Course on Revascularization; 2006 May 10-19; Paris: EuroPCR, 2006
57. Serruys PW. Drug-eluting stents: results from clinical trials. The PISCES trials [lecture]. 55th Annual Scientific Session of the American College of Cardiology; 2006 Mar 11-14; Atlanta (GA): American College of Cardiology, 2006
58. Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry. J Am Coll Cardiol 2005; 45: 1574-9
59. Serruys PW, on behalf of the HEALING II Investigators. The genous endothelial capture system. Final results from the HEALING II Study [abstract]. TCT2005, The Drug-Eluting Stent Summit; 2005 Oct 16-21; Washington, DC: The Cardiovascular Foundation, 2005
60. Duckers H, Aoki J, de Heer H, et al. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions: an interim analysis of the HEALING II trial using an endothelial progenitor cell capturing stent (Genous R Stent) [abstract no. TCT15]. Am J Cardiol 2005; 96 Suppl. 7A: 7H
61. Windecker S, Mayer I, De Pasquale G, et al. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation 2001; 104: 928-33
62. Windecker S, Simon R, Lins M, et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation 2005; 111: 2617-22
63. Dibra A, Kastrati A, Alfonso F, et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol 2007; 49: 616-23
64. Liu X, Huang Y, Hanet C, et al. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv 2003; 60: 172-8
65. De Scheerder I. The Abbott vascular devices dexamethasone eluting stent: from STRIDE to the 'real-world' SAFE registry [lecture]. 15th Annual Transcatheter Cardiovascular Therapeutics (TCT 2003) Scientific Symposium; 2003 Sep 15-19; Washington, DC: Cardiovascular Research Foundation, 2003